Hervana Bio Overview
Hervana Bio is a biopharmaceutical company that develops womens health products. The company has developed a female contraceptive platform technology that is non-hormonal and offers protection against sexually transmitted infections. Hervanas LJ-102 is a highly effective, long-lasting contraceptive technology free from the drawbacks of current hormone-based contraceptives. The products safety profile and prolonged action enable greater compliance and accessibility, particularly in populations where the available methods of contraception are contraindicated, undesirable, or socially unacceptable. In 2012, Hervana Bio received a $1 million grant from the Bill and Melinda Gates Foundation.
Latest News
growth-positive
The Israeli startup developing the first new, non-hormonal contraceptive in 60 years | CTech
Hervana Bio, a biopharmaceutical company, is developing a non-hormonal contraceptive with added protection against sexually transmitted infections (STIs). The contraceptive is based on lactobacilli, a bacteria found in the female reproductive tract, and is currently in the trial stage with a reported 100% efficacy rate. The contraceptive also has the potential to prevent STIs. The company is seeking additional funding to further develop and market the product. The contraceptive market is valued at $20 billion and is expected to reach $25 billion by 2027.
Investment
growth-positive
Hervana Bio Founder and CEO Dr. Rachel Teitelbaum Provides Update on Female Contraceptive Development at Microbiome EU Summit
Hervana Bios CEO, Rachel Teitelbaum, has presented an update on the development of HER-102, a reversible female contraceptive, at the Microbiome Drug Development Summit Europe. The contraceptive harnesses the power of antibodies to prevent pregnancy and protect against sexually transmitted infections, including HIV. The contraceptive effect has been shown to be fully reversible, with no negative effects in preliminary toxicology studies. Hervana Bio is an Israeli-based biopharmaceutical company dedicated to innovating products in womens health.
InvestmentExpand
growth-positive
Bill Gates Grants Hervana $1M for Contraceptive
Hervana has been awarded a $1 million grant from the Bill & Melinda Gates Foundation for the development of a long-acting, non-hormonal contraceptive platform technology. The grant will support the creation of a vaginal suppository that only needs to be applied once or twice a month, providing a low-cost and non-invasive contraceptive option. The CEO and founder of Hervana, Rachel Teitelbaum, highlights the need for a contraceptive free of health risks and medical procedures, especially in developing countries where there is a lack of accessible options. The Gates Foundation is excited about this application for the developing world, as there are over 220 million women without access to effective contraception and 50 million abortions per year in the developing world.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.1M |
| Last funding | $1M |
| Stage | Pre-Funding |
| Rounds | 2 |
| Investors | 0 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | hervana-bio.com |
Locations
Naftali Street 9, Jerusalem, Israel
Photos & Videos
1 item(s)
Hervana Bio Business
Business models
B2B, B2B2C
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
ConsumersDemographics & FamilyWomenHealthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsTags (6)
pregnancybiotechnologywomen-healthpharmaceuticalswomenfemtechGeographic Markets
United StatesHervana Bio Financials
$1.1M
Total funding
—
Capital raised
$1M
Last funding
Pre-Funding
Funding stage
2
Total rounds
0
Investors
Non-Equity Funding
GrantEvent
Dec 2012
$1M
Bill & Melinda Gates Foundation
GrantEvent
May 2010
$100K
Bill & Melinda Gates Foundation
Hervana Bio Lifecycle
All Events
GrantEvent
Dec 2012
$1M
Bill & Melinda Gates Foundation
GrantEvent
May 2010
$100K
Bill & Melinda Gates Foundation
Hervana Bio News
3 articles
growth-positive
The Israeli startup developing the first new, non-hormonal contraceptive in 60 years | CTech
Hervana Bio, a biopharmaceutical company, is developing a non-hormonal contraceptive with added protection against sexually transmitted infections (STIs). The contraceptive is based on lactobacilli, a bacteria found in the female reproductive tract, and is currently in the trial stage with a reported 100% efficacy rate. The contraceptive also has the potential to prevent STIs. The company is seeking additional funding to further develop and market the product. The contraceptive market is valued at $20 billion and is expected to reach $25 billion by 2027.
Investment
growth-positive
Hervana Bio Founder and CEO Dr. Rachel Teitelbaum Provides Update on Female Contraceptive Development at Microbiome EU Summit
Hervana Bios CEO, Rachel Teitelbaum, has presented an update on the development of HER-102, a reversible female contraceptive, at the Microbiome Drug Development Summit Europe. The contraceptive harnesses the power of antibodies to prevent pregnancy and protect against sexually transmitted infections, including HIV. The contraceptive effect has been shown to be fully reversible, with no negative effects in preliminary toxicology studies. Hervana Bio is an Israeli-based biopharmaceutical company dedicated to innovating products in womens health.
InvestmentExpand
growth-positive
Bill Gates Grants Hervana $1M for Contraceptive
Hervana has been awarded a $1 million grant from the Bill & Melinda Gates Foundation for the development of a long-acting, non-hormonal contraceptive platform technology. The grant will support the creation of a vaginal suppository that only needs to be applied once or twice a month, providing a low-cost and non-invasive contraceptive option. The CEO and founder of Hervana, Rachel Teitelbaum, highlights the need for a contraceptive free of health risks and medical procedures, especially in developing countries where there is a lack of accessible options. The Gates Foundation is excited about this application for the developing world, as there are over 220 million women without access to effective contraception and 50 million abortions per year in the developing world.
Customers
Hervana Bio Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 2 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Hervana Bio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | funding rounds, markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 514154038 |
| Crunchbase | hervana |
| Creator | Arielle Smolin |
| Creator email | ari.smolin@gmail.com |
| Last updater | Paul Weisko |
| Updater email | pweisko@gmail.com |
| Last update | 2021-04-18T00:00:00.000Z |
| Created | 2014-07-16T00:00:00.000Z |